Accumulation of (18)F-FDG in the liver in hepatic steatosis

AJR Am J Roentgenol. 2014 Sep;203(3):643-8. doi: 10.2214/AJR.13.12147.

Abstract

Objective: Nonalcoholic fatty liver disease is associated with hepatic inflammation. An emerging technique to image inflammation is PET using the glucose tracer, (18)F-FDG. The purpose of this study was to determine whether in hepatic steatosis the liver accumulates FDG in excess of FDG physiologically exchanging between blood and hepatocyte.

Materials and methods: Hepatic FDG uptake, as SUV = [voxel counts / administered activity] × body weight), and CT density were measured in a liver region in images obtained 60 minutes after injection of FDG in 304 patients referred for routine PET/CT. Maximum SUV (region voxel with the highest count rate, SUVmax) and average SUV ( SUVave) were measured. Blood FDG concentration was measured as the maximum SUV over the left ventricular cavity (SUVLV). SUVave was adjusted for hepatic fat using a formula equating percentage fat to CT density. Patients were divided in subgroups on the basis of blood glucose (< 4, 4 to < 5, 5 to < 6, 6 to < 8, 8 to < 10, and > 10 mmol/L). Hepatic steatosis was defined as CT density less than 40 HU (n = 71).

Results: The percentage of hepatic fat increased exponentially with blood glucose. SUVmax / SUVLV and fat-adjusted SUVave / SUVLV but not SUVave / SUVLV correlated with blood glucose. Fat-adjusted SUVave was higher in patients with hepatic steatosis (p < 0.001) by ~0.4 in all blood glucose groups. There was a similar difference (~0.3) in SUVmax (p < 0.005) but no difference in SUVave. SUVmax / SUVLV and fat-adjusted SUVave / SUVLV correlated with blood glucose in patients with hepatic steatosis but not in those without. SUVave / SUVLV correlated with blood glucose in neither group.

Conclusion: FDG uptake is increased in hepatic steatosis, probably resulting from irreversible uptake in inflammatory cells superimposed on reversible hepatocyte uptake.

Keywords: FDG; PET; blood glucose; hepatic steatosis; liver.

Publication types

  • Duplicate Publication
  • Randomized Controlled Trial

MeSH terms

  • Computer Simulation
  • Fatty Liver / diagnostic imaging*
  • Fluorodeoxyglucose F18 / blood
  • Fluorodeoxyglucose F18 / pharmacokinetics*
  • Humans
  • Image Interpretation, Computer-Assisted / methods*
  • Liver / diagnostic imaging*
  • Liver / metabolism*
  • Models, Biological
  • Positron-Emission Tomography / methods*
  • Radiopharmaceuticals / pharmacokinetics
  • Reproducibility of Results
  • Sensitivity and Specificity
  • Up-Regulation

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18